Top Page
HUTCHMED (China)
(0013)
HUTCHMED (China) (0013) vs. iShares MSCI Hong Kong ETF (EWH)
HUTCHMED (China) Business Overview & Revenue Model
HUTCHMED (China) Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 602.20M | 630.20M | 838.00M | 426.41M | 356.13M | 227.98M |
| Gross Profit | 53.76M | 281.32M | 151.55M | 115.31M | 97.89M | 39.46M |
| EBITDA | -7.49M | 14.11M | 67.27M | -401.11M | -321.13M | -182.89M |
| Net Income | 466.88M | 37.73M | 100.78M | -360.83M | -194.65M | -125.73M |
Balance Sheet | ||||||
| Total Assets | 1.78B | 1.27B | 1.28B | 1.03B | 1.37B | 724.12M |
| Cash, Cash Equivalents and Short-Term Investments | 1.36B | 836.11M | 886.34M | 631.00M | 1.01B | 439.04M |
| Total Debt | 93.44M | 89.82M | 86.13M | 27.01M | 38.98M | 35.71M |
| Total Liabilities | 534.02M | 502.34M | 536.39M | 392.57M | 333.15M | 205.17M |
| Stockholders Equity | 1.23B | 759.93M | 730.54M | 610.37M | 986.89M | 484.12M |
Cash Flow | ||||||
| Free Cash Flow | -49.66M | -17.44M | 186.65M | -305.26M | -220.98M | -81.65M |
| Operating Cash Flow | -32.56M | 497.00K | 219.26M | -268.60M | -204.22M | -62.07M |
| Investing Cash Flow | -73.03M | -96.06M | -291.14M | 296.59M | -306.32M | -125.44M |
| Financing Cash Flow | 11.22M | -30.67M | 48.66M | -82.76M | 650.03M | 296.43M |
HUTCHMED (China) Technical Analysis
HUTCHMED (China) Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$28.65B | 13.30 | 12.65% | 3.13% | 10.56% | -13.58% | |
68 Neutral | HK$29.03B | 9.55 | 5.90% | 2.95% | ― | ― | |
65 Neutral | HK$34.06B | 19.05 | 10.01% | 2.26% | 11.78% | 19.06% | |
64 Neutral | HK$23.64B | 6.53 | 21.02% | 5.11% | 0.39% | 4.94% | |
53 Neutral | HK$19.59B | 5.57 | 48.58% | ― | -1.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
HUTCHMED (China) Corporate Events
HUTCHMED has initiated a global Phase I clinical development program for HMPL-A251, a first-in-class Antibody-Targeted Therapy Conjugate (ATTC) designed to treat patients with HER2-expressing solid tumors. This trial, conducted in the US and China, marks the first clinical-stage candidate from HUTCHMED’s next-generation ATTC platform, aiming to improve targeted delivery and reduce systemic toxicity. The development of HMPL-A251 could potentially enhance HUTCHMED’s positioning in precision oncology by offering a novel approach to overcoming challenges associated with existing PAM-targeted therapies, thus benefiting stakeholders by expanding treatment options and improving patient outcomes.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited has announced the renewal of its contract with the China National Healthcare Security Administration, ensuring continued inclusion of its drugs ELUNATE®, ORPATHYS®, and SULANDA® in the National Reimbursement Drug List (NRDL) effective January 2023. Additionally, TAZVERIK® has been added to the first edition of the National Commercial Health Insurance Innovative Drug List, which is part of China’s multi-level medical insurance system. This development enhances patient access to innovative treatments and supports the sustainable growth of China’s pharmaceutical sector.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED announced that it will present new and updated clinical data from several of its drug studies at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting. These presentations include results from studies on treatments for advanced solid tumors, renal cell carcinoma, pancreatic cancer, and non-small cell lung cancer, among others. The announcement highlights HUTCHMED’s ongoing efforts to advance its drug development pipeline and strengthen its position in the oncology and immunotherapy markets.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED has completed patient enrollment for the SAFFRON Phase III trial, which investigates the combination of ORPATHYS® and TAGRISSO® as a treatment for NSCLC patients with MET overexpression after progression on TAGRISSO®. This trial could potentially lead to global regulatory filings if results are favorable, marking a significant step in offering a chemotherapy-free treatment option for lung cancer patients.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited announced significant advancements in its research and development efforts, particularly highlighting its new Antibody-Targeted Therapy Conjugate (ATTC) platform, which integrates monoclonal antibodies with small-molecule inhibitors to enhance precision oncology. The lead candidate, HMPL-A251, shows promising preclinical results in targeting the PAM pathway, with plans to enter clinical development by late 2025. Additionally, HUTCHMED reported progress in several late-stage clinical trials, including studies on fruquintinib, savolitinib, surufatinib, sovleplenib, and fanregratinib, indicating potential advancements in treatment options for various cancers and immunological conditions.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited announced promising preclinical data for its investigational drug candidate, HMPL-A251, at an international conference. This drug, part of their ATTC platform, combines a potent PI3K/PIKK inhibitor with an anti-HER2 antibody to target cancer cells more effectively and with reduced toxicity compared to traditional therapies. The data showed strong antitumor activity and a favorable safety profile, positioning HMPL-A251 as a potential breakthrough in cancer treatment. HUTCHMED plans to initiate global clinical trials for HMPL-A251 by the end of 2025, aiming to redefine cancer treatment with more ATTC candidates in the pipeline.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED (China) Limited has announced the composition of its Board of Directors, which includes a mix of executive, non-executive, and independent non-executive directors. The announcement provides details on the roles and committee memberships of each director, reflecting the company’s governance structure and its commitment to diverse leadership. This update is significant for stakeholders as it outlines the leadership team responsible for steering the company’s strategic direction and operational oversight.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED announced significant results from the FRUSICA-2 registration trial, showcasing the efficacy of the fruquintinib and sintilimab combination in treating advanced renal cell carcinoma. The trial demonstrated notable improvements in progression-free survival and objective response rates compared to existing monotherapies, indicating the potential of this combination to enhance second-line treatment strategies for this challenging disease. The results have led to a New Drug Application being accepted for review by the China National Medical Products Administration, potentially impacting treatment options for renal cell carcinoma patients.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
HUTCHMED announced that it will present new and updated clinical data from several studies at the ESMO Congress 2025 in Berlin. The presentations will include results from the FRUSICA-2 study on the combination of fruquintinib and sintilimab for renal cell carcinoma, as well as analyses of studies involving fruquintinib in endometrial and colorectal cancer, and savolitinib in non-small cell lung cancer. These data presentations underscore HUTCHMED’s ongoing efforts to advance its oncology pipeline and strengthen its position in the cancer treatment market.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.